Literature DB >> 3319637

Nicardipine in the treatment of essential hypertension controlled 6-month-study comparing nicardipine with propranolol at rest and during exercise.

A Danielsson1, P Bjerle, B Ek, L Steen, O Suhr.   

Abstract

Thirty patients with mild to moderate essential hypertension entered a randomised double-blind parallel group study for 6 months to compare the effects of the new calcium channel blocker nicardipine 90 mg/day and propranolol 240 mg/day. Both drugs reduced systolic and diastolic blood pressures significantly in the supine and in standing positions. After 6 months of treatment, nicardipine had reduced the supine systolic and diastolic blood pressures by 16 and 17 mm Hg, respectively, and propranolol by 15 and 12 mm Hg. While propranolol treatment led to a marked decline in heart rate, nicardipine caused a small but statistically significant increase in heart rate throughout the study. Both drugs reduced blood pressure during maximal exercise, but propranolol had a greater effect. During exercise nicardipine did not affect the heart rate, whereas propranolol dramatically reduced it. Nicardipine did not produce any ECG changes at rest or during exercise. The side-effects for nicardipine were mild and were related to the vasodilatation induced by the drug. No abnormalities in routine blood chemical tests were found for either of the drugs. Nicardipine appears to be an effective single drug treatment for mild to moderate hypertension.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319637     DOI: 10.1007/BF00610373

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  The effect of nifedipine on the sinus and atrioventricular node of the dog heart after beta-adrenergic receptor blockade.

Authors:  J P Amlie; K Landmark
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978-04

2.  Pharmacokinetics of nicardipine following oral and intravenous administration in man.

Authors:  D J Graham; R J Dow; D Freedman; E Mroszczak; T Ling
Journal:  Postgrad Med J       Date:  1984       Impact factor: 2.401

3.  Acute haemodynamic effects of a new calcium antagonist, nicardipine, in man. A comparison with nifedipine.

Authors:  A Iliopoulou; P Turner; S J Warrington
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

4.  Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade.

Authors:  K Aoki; S Kondo; A Mochizuki; T Yoshida; S Kato; K Kato; K Takikawa
Journal:  Am Heart J       Date:  1978-08       Impact factor: 4.749

5.  Cerebrovascular effects of YC-93, a new vasodilator, in dogs, monkeys and human patients.

Authors:  T Takenaka; J Handa
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-01

6.  Nicardipine hydrochloride in essential hypertension--a controlled study.

Authors:  J Asplund
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

7.  Hypotensive action and increased plasma renin activity by Ca2+ antagonist (Nifedipine) in hypertensive patients.

Authors:  K Aoki; T Yoshida; S Kato; K Tazumi; I Sato
Journal:  Jpn Heart J       Date:  1976-07

8.  Effects of treatment with nifedipine and metoprolol in essential hypertension.

Authors:  R Eggertsen; L Hansson
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Baroreflex setting and sensitivity after acute and chronic nicardipine therapy.

Authors:  M A Young; R D Watson; W A Littler
Journal:  Clin Sci (Lond)       Date:  1984-02       Impact factor: 6.124

10.  Hemodynamic effects of verapamil in essential hypertension at rest and during exercise.

Authors:  P Lund-Johansen
Journal:  Acta Med Scand Suppl       Date:  1984
View more
  1 in total

1.  Antihypertensive effect of slow-release nicardipine. A placebo-controlled cross-over study.

Authors:  A Salvetti; G Cardellino; M Pesenti; A Caiazza; F Ghisoni; C Del Prato; P F Innocenti; F Ponzanelli; M Errico; M Freda
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.